Roche (OTCMKTS:RHHBY) Rating Lowered to “Strong Sell” at Zacks Research

by · The Markets Daily

Roche (OTCMKTS:RHHBY – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities analysts also recently weighed in on RHHBY. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price for the company in a research note on Friday, April 24th. HSBC downgraded shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $51.50.

Get Our Latest Stock Analysis on Roche

Roche Stock Up 2.0%

Shares of RHHBY opened at $51.18 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a 1 year low of $37.51 and a 1 year high of $60.85. The stock’s fifty day moving average price is $51.32 and its two-hundred day moving average price is $52.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RHHBY. Opal Capital LLC purchased a new stake in Roche in the first quarter valued at approximately $4,448,000. S&CO Inc. grew its stake in Roche by 163.0% in the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock worth $6,880,000 after buying an additional 87,107 shares in the last quarter. Meritage Portfolio Management bought a new position in shares of Roche in the 4th quarter worth $4,372,000. Hantz Financial Services Inc. raised its position in shares of Roche by 164.9% during the 4th quarter. Hantz Financial Services Inc. now owns 79,732 shares of the company’s stock valued at $4,112,000 after buying an additional 49,633 shares in the last quarter. Finally, IHT Wealth Management LLC bought a new stake in shares of Roche during the 4th quarter worth $400,000.

Roche Company Profile

(Get Free Report)

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

Recommended Stories